Menu

Teva Pharmaceutical Industries Limited TEVA

Full chart Compare
Set alert

Price alert · TEVA

All alert types
41.78 USD -0.07 (-0.17%)

At closeNov 5, 2026, 7:23 PM EST

41.80 +0.02 +0.05%

After hours · Nov 5, 7:23 PM ET

40.92 Day range 42.38
23.61 52-week range 43.34
YTD
+33.87%
1 year
+69.84%
Market cap
48.75B
Revenue (ttm)
17.23B
Profit margin
2.94%
EPS (ttm)
0.43
Shares out
1.17B
P/E ratio
97.16
Forward P/E
13.49
YTD return
+33.87%
1-year return
+69.84%
Volume
13.63M
Avg volume
5.79M
Open
41.49
Previous close
41.85
Day's range
40.92 – 42.38
52-week range
23.61 – 43.34
Analysts
Buy
Price target
48.94 (+17.1%)
Earnings date
Jan 27, 2027

5D -0.11 (-0.26%)

414243FriMonTueWedThu41.78

Key statistics

Enterprise value
61.77B
PEG ratio
0.71
Price / sales
2.83
Price / book
6.08
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
-1.90%
Free cash flow
1.21B
Total cash
4.08B
Total debt
16.98B
Return on equity
6.65%
Short % of float
2.42%
50-day average
39.25
200-day average
34.67

Financials — quick view

All financials
TEVA Revenue — quarterly 4.39B
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
TEVA Net income — quarterly 233.00M
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026
TEVA EPS — quarterly 0.20
2022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 20262026-Q3 2026

Earnings

TEVA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Jan 27, 2027Dec 30, 20260.696———
Nov 3, 2026Sep 30, 20260.720.86+0.14+19.44%
Jul 29, 2026Jun 30, 20260.080.02-0.06-75.00%
Apr 29, 2026Mar 31, 20260.500.53+0.03+6.00%
Jan 28, 2026Dec 31, 20250.650.96+0.31+47.69%
Nov 5, 2025Sep 30, 20250.680.78+0.10+14.71%

Upgrades / downgrades

TEVA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 4, 2026TD CowenmainBuyBuy
Nov 4, 2026HC Wainwright & Co.mainBuyBuy
Nov 2, 2026HC Wainwright & Co.init—Buy
Oct 15, 2026BarclaysmainOverweightOverweight
Oct 12, 2026JP MorganmainOverweightOverweight
Oct 1, 2026TD Coweninit—Buy

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
Israel

News

Your note

Sign in to keep a note on TEVA — it syncs with the Stock Master app.

Insider holders

TEVA insider holders
InsiderRelationLatest transactionDateShares held
BARER SOL JDirectorConversion of Exercise of derivative securityJun 4, 2026448,011
CRANE ROSEMARY ADirectorConversion of Exercise of derivative securityJun 4, 2026127,739
ELSTEIN AMIRDirectorConversion of Exercise of derivative securityJun 4, 20262,118,460
FOX CHRISTINEOfficerSaleMar 3, 202675,010
FRANCIS RICHARD DChief Executive OfficerSaleJun 4, 20261,177,530
HUGHES ERIC AOfficerSaleAug 2, 2026134,877

Institution ownership

TEVA institution ownership
Holder% heldSharesValueReported
Blackrock Inc.5.48%63,894,3012.67BJun 29, 2026
Phoenix Financial Ltd.3.68%42,933,3671.80BJun 29, 2026
WCM Investment Management, LLC3.55%41,315,2321.73BJun 29, 2026
Clal Insurance Enterprises Holdings Ltd3.48%40,596,5061.70BJun 29, 2026
Menora Mivtachim Holdings Ltd.3.42%39,854,3831.67BJun 29, 2026
Migdal Insurance & Financial Holdings Ltd.3.34%38,922,2121.63BJun 29, 2026

Fund ownership

TEVA fund ownership
Holder% heldSharesValueReported
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund1.47%17,083,534714.43MJul 30, 2026
INVESTMENT MANAGERS SERIES TRUST-WCM Focused International Growth Fund1.10%12,781,190534.51MSep 29, 2026
New Economy Fund1.06%12,327,600515.54MSep 29, 2026
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund0.97%11,344,396474.42MJun 29, 2026
iShares Trust-iShares Core MSCI EAFE ETF0.76%8,854,390370.29MSep 29, 2026
Fidelity Rutland Square TRT II-Strategic Advisers Fidelity Intl Fd.0.40%4,663,445195.03MAug 30, 2026